ASAN-Imperial Symposium
About AMC > International Cooperation > ASAN-Imperial Symposium
The 3rd ASAN-Imperial Symposium
Lung and Breast Cancers
April 15, 2010
| No. | Speaker | Organization | Title |
|---|---|---|---|
| 10 | Hee Jung Shin, MD, PhD | Asan Medical Center | Evaluation of Responses to Neoadjuvant Chemotherapy in Patients with Breast Cancer Using Proton MR Spectroscopy |
| 9 | Hee Jeong Kim, MD, PhD | Asan Medical Center | Prognostic Effects of Serum 25 Hydroxyvitamin D Levels in Breast Cancer Patients |
| 8 | Eric Lim, MD | Royal Brompton Hospital, Imperial College London |
Surgical Research in Lung Cancer |
| 7 | Sang-We Kim, MD | Asan Medical Center | Role of PET during Chemotherapy for NSCLC |
| 6 | Michael J. Seckl, MD, PhD | Hammersmith Hospital, Imperial College London |
Identification of Novel Chemoresistance and Metastasis Mechanisms in Lung Cancer |
| 5 | Jin-Hee Ahn, MD, PhD | Asan Medical Center | Neoadjuvant Chemotherapy in Breast Cancer: AMC Experience |
| 4 | R Charles Coombes, MD, PhD | Hammersmith Hospital, Imperial College London |
New Approaches to Endocrine Resistant Breast Cancer |
| 3 | Eric W. Lam, MBA, PhD | Hammersmith Hospital, Imperial College London |
Role and Regulation of FOXO-FOXM1 Forkhead Transcription Factor Axis in Breast Cancer and Chemotherapy Resistance |
| 2 | Se Jin Jang, MD, PhD | Asan Medical Center | RASSF1A Gene Hypermethylation in Lung Cancer Cells and Tissues in Association with Overexpression of miR-200c |
| 1 | Francesco A. Mauri, MD | Hammersmith Hospital, Imperial College London |
mTOR as a Theranostic in Lung Cancer |
